<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>521</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15386261</PubmedId>
            <Abstract>The 16-kDa protein of Mycobacterium tuberculosis provokes specific immune responses; it is thus a target for the development of peptide-based diagnostic reagents and subunit vaccines. Previous studies have demonstrated the presence of several regions containing murine and human T-cell epitopes. Within the 91-110 immunodominant domain, we found that peptides comprising the sequence of 91SEFAYGSFVRTVSL104 elicit specific T-cell responses in both human T-cell clones and human peripheral blood mononuclear cells (PBMC) from PPD+ (purified protein derivative) individuals. Elongation of this peptide towards the C-terminal end did not provide more effective peptides, but the removal of residue 91Ser resulted in an almost complete loss of functionality. However, the introduction of an acetyl group at the N-terminal of residue 92Glu produced a shorter peptide (Ac-92EFAYGSFVRTVSL104) exhibiting properties required for efficient T-cell responses. CD measurements indicated that peptide 91SEFAYGSFVRTVSLPVGADE110 adopts a helical conformation in trifluoroethanol. We found that the N-terminal part of this sequence plays a major role in the induction of proliferative T-cell responses and is responsible for the highly ordered, helical secondary structure. The "lead" structure described here could also be considered in the development of synthetic peptides or multicomponent peptide mixtures for the early detection, monitoring, or preventing Mycobacterium tuberculosis infection with optimized T-cell response-provoking capacity.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>467-76</ArticlePages>
            <ArticleTitle>In vitro T-cell immunogenicity of oligopeptides derived from the region 92-110 of the 16-kDa protein of Mycobacterium tuberculosis.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Bosze</LastName>
                    <ForeName>Szilvia</ForeName>
                </Author>
                <Author>
                    <LastName>Caccamo</LastName>
                    <ForeName>Nadia</ForeName>
                </Author>
                <Author>
                    <LastName>Majer</LastName>
                    <ForeName>Zsuzsa</ForeName>
                </Author>
                <Author>
                    <LastName>Mezo</LastName>
                    <ForeName>Gábor</ForeName>
                </Author>
                <Author>
                    <LastName>Dieli</LastName>
                    <ForeName>Francesco</ForeName>
                </Author>
                <Author>
                    <LastName>Hudecz</LastName>
                    <ForeName>Ferenc</ForeName>
                </Author>
            </Authors>
            <Affiliations>Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eôtvos L. University Budapest 112, POB 32, H-1518, Hungary.</Affiliations>
            <ArticleChemicalList>Bacterial Proteins;Epitopes;Oligopeptides;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Bacterial Proteins(chemistry; immunology); Epitopes(chemistry); Humans; In Vitro Techniques; Interferon-gamma(biosynthesis); Mice; Molecular Sequence Data; Molecular Weight; Mycobacterium tuberculosis(chemistry; immunology); Oligopeptides(chemistry; immunology; pharmacology); Protein Structure, Secondary; T-Lymphocytes(drug effects; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>76</Volume>
                <Issue>6</Issue>
                <Title>Biopolymers.</Title>
                <Issn>1079-0282</Issn>
                <MedlineTa>Biopolymers</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>&lt;sup&gt;91&lt;/sup&gt;SEFAYGSFVRTVSL&lt;sup&gt;104&lt;/sup&gt;</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SEFAYGSFVRTVSL</LinearSequence>
                        <StartingPosition>91</StartingPosition>
                        <EndingPosition>104</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P0A5B7.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1773</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table I</LocationOfData>
                <EpitopeId>57415</EpitopeId>
                <ReferenceStartingPosition>91</ReferenceStartingPosition>
                <ReferenceEndingPosition>104</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>8077</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>33892</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>PBMCs were taken from healthy donors that were PPD positive. Previous vaccination with BCG is assumed.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SEFAYGSFVRTVSLP</LinearSequence>
                                        <StartingPosition>91</StartingPosition>
                                        <EndingPosition>105</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5B7.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>3464</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of infectious disease</InVivoProcessType>
                                <DiseaseState>DOID:399</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>1773</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Mycobacterium tuberculosis</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Six T-cell clones were generated from the peripheral blood (4 clones) or body fluid (two clones) of TB patients.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>T cell CD4+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>304</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -MHC subset identification</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>&lt;sup&gt;91&lt;/sup&gt;SEFAYGSFVRTVSL&lt;sup&gt;104&lt;/sup&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SEFAYGSFVRTVSL</LinearSequence>
                                        <StartingPosition>91</StartingPosition>
                                        <EndingPosition>104</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0A5B7.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1773</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>All peptides comprising the sequence SEFAYGSFVRTVSL stimulated IFN-γ production in all six clones.  The peptide Ac-EFAYGSFVRTVSL, which was acetylated at the N-terminal glutamic acid, also stimulated responses in all six clones, while further truncations reduced responses.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

